Pacific Therapeutics Enters into Agreement with University of British Columbia to Perform Studies using Lead Candidate, PTL-101
Pacific Therapeutics Ltd. announced that it has entered into an eight month contract with the University of British Columbia to perform animal studies with the company's lead candidate PTL-101.
The work will be conducted by Dr. Nasreen Khalil, MD, PhD, FRCPC, and FCCP. Dr. Khalil is an Associate Professor of Medicine at The University of British Columbia. In addition to her research activities Dr. Khalil has an active respirology clinic at the Vancouver Hospital Lung Centre. According to the company, she was the first scientist to describe the association of TGF-B1 with the pathogenesis of pulmonary fibrosis. In addition Dr. Khalil was the first scientist to demonstrate an aberrant expression of TGF-B1 by epithelial cells of lungs in patients with the deadly disease, idiopathic pulmonary fibrosis (IPF). At present there is no effective treatment for chronic lung transplant rejection, IPF and other progressive fibrotic diseases.
Under the contract Dr. Khalil and her team will be conducting experiments to provide data for the filing of an investigational New Drug Application (IND) with the US Food and Drug Administration. Partial funding for his research has been granted to Dr. Khalil from the Canadian Institutes of Health Research (CIHR) under the Proof of Principal II program (POP II).
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
